MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Open accessAbstract
MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA. MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants. The underlying psychological and neurological mechanisms for the robust effects in mitigating PTSD are being investigated in animal models and in studies of healthy volunteers. This review explores the potential role of memory reconsolidation and fear extinction during MDMA-assisted psychotherapy. MDMA enhances release of monoamines (serotonin, norepinephrine, dopamine), hormones (oxytocin, cortisol), and other downstream signaling molecules (BDNF) to dynamically modulate emotional memory circuits. By reducing activation in brain regions implicated in the expression of fear- and anxiety-related behaviors, namely the amygdala and insula, and increasing connectivity between the amygdala and hippocampus, MDMA may allow for reprocessing of traumatic memories and emotional engagement with therapeutic processes. Based on the pharmacology of MDMA and the available translational literature of memory reconsolidation, fear learning, and PTSD, this review suggests a neurobiological rationale to explain, at least in part, the large effect sizes demonstrated for MDMA in treating PTSD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MDMA's empathogenic and neurocognitive properties make it a promising facilitator of CBCT for PTSD.
“MDMA’s (3,4-methylenedioxymethamphetamine) empathogenic and neurocognitive properties make it a promising facilitator of this trauma-focused, empirically supported relational therapy (e.g. Feduccia & Mithoefer, 2018).”
From MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial (2020) · cites this paper as Feduccia & Mithoefer, 2018
The Introduction describes MDMA’s effects as enhancing introspection and the therapeutic alliance, while §2.3 (Oxytocin) discusses its prosocial effects and possible role in psychotherapy. The paper also reviews effects on emotional memory processing in §2. These passages support the proposed rationale for MDMA-assisted PTSD therapy generally, but do not establish that MDMA facilitates CBCT specifically. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 105 · Cited by 217
Research works printed but not linked: 7
- Bradley, R., Greene, J., Russ, E., Dutra, L., Westen, D., 2005. A multidimensional meta- analysis of psychotherapy for PTSD. Am. J. Psychiatry 162 (2), 214-227.
- Hope, R., 2015. In: McMillan, K. (Ed.), Is Ecstasy the Key to Treating Women with PTSD? Marie Claire.
- Huston, V., 2015. In: McKay, T. (Ed.), Meet the Iraq War Veteran Who Says Ecstasy- assisted Psychotherapy Saved His Life. Mic.
- Mithoefer, M., 2013. MDMA-assisted psychotherapy: how different is it from other psy- chotherapy? MAPS Bull. 23 (1), 10-14.
- U. S. A. 108 (16), 6621-6625.
- Vaidya, V.A., Marek, G.J., Aghajanian, G.K., Duman, R.S., 1997. 5-HT2A receptor- mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17 (8), 2785-2795.
- Withem, H., 2016. Speaking My Truth: My Experience of MDMA-assisted Psychotherapy. MAPS Bull. 26 (2) (Research Edition).
- Authors
- Feduccia, A. A., & Mithoefer, M. C.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Feduccia, Allison A.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 84
- Issue
- Pt A
- Pages
- 221-228
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2792164490
- Cited by
- 217
- References
- 105
- Citations by year
- 2026: 25 · 2025: 30 · 2024: 34 · 2023: 31 · 2022: 36 · 2021: 23 · 2020: 14 · 2019: 18 · 2018: 5
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Multidisciplinary Association for Psychedelic Studies
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, memory reconsolidation, fear extinction, monoamines, oxytocin, cortisol, brain-derived neurotrophic factor, amygdala, insula, emotional memory, therapeutic mechanisms
- MeSH terms
- Animals, Clinical Trials as Topic, Combined Modality Therapy, Humans, Psychotherapy, Psychotropic Drugs, Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
